Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial

Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial

Aims This study aimed to explore the rapid effects of dapagliflozin in heart failure with reduced ejection fraction (HFrEF). Methods and results We studied the functional, echocardiographic, electrophysiological, lung ultrasound, ambulatory blood pressure (BP), microvascular and macrovascular functi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ESC Heart Failure 2021-10, Vol.8 (5), p.4346-4352
Hauptverfasser: Ilyas, Fahmida, Jones, Lynette, Tee, Su Ling, Horsfall, Matthew, Swan, Amy, Wollaston, Fiona, Hecker, Tracy, De Pasquale, Carla, Thomas, Simeoni, Chong, William, Stranks, Steve, Mangoni, Arduino A., Selvanayagam, Joseph B., Chew, Derek P., De Pasquale, Carmine G.
Format: Artikel
Sprache:eng
Schlagworte:
Acute effects
Antidiabetics
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
Creatinine
Dapagliflozin
Diabetes
Ejection fraction
Heart failure
Heart rate
Hemoglobin
HFrEF
Life Sciences & Biomedicine
Mechanism
Quality of life
Science & Technology
Short Communication
Short Communications
Standard deviation
Tomography
Ultrasonic imaging
Veins & arteries
Velocity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims This study aimed to explore the rapid effects of dapagliflozin in heart failure with reduced ejection fraction (HFrEF). Methods and results We studied the functional, echocardiographic, electrophysiological, lung ultrasound, ambulatory blood pressure (BP), microvascular and macrovascular function, and biochemical effects of 2 week treatment with dapagliflozin in 19 type 2 diabetic HFrEF patients in a double‐blind, crossover, placebo‐controlled trial. Dapagliflozin had no significant effect on clinical, functional, or quality of life parameters. Dapagliflozin reduced systolic BP [114 (105, 131) vs. 106 (98, 113) mmHg, P 
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.13553